Manu P. Kumar
YOU?
Author Swipe
View article: Supplementary Figure S6 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S6 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S6: Characterization of antigen-specific CD8+ T cells in MC38 tumors.
View article: Supplementary Figure S3 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S3 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S3: Biodistribution of cytokine fusion molecules in tumor-bearing mice.
View article: Supplementary Figure S9 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S9 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S9: scRNAseq analysis of MC38 tumors.
View article: Supplementary Figure S5 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S5 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S5: Anti-tumor activity of CD8-mIL2 in combination with anti-PD-1 in B16F10, 1956, MCA-205, and KP.mLama4 tumor models.
View article: Supplementary Figure S2 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S2 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S2: In vitro culture of human CD8+ T cells, evaluation of CD8α and CD8β expression, and cytokine release assessment.
View article: Supplementary Figure S1 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S1 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S1: CD8+ T cells drive anti-tumor activity but NK cells are responsible for toxicity with not-α-IL2 therapy.
View article: Supplementary Figure S10 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S10 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S10: In vitro and in vivo activity of AB248 in cynomolgus monkey.
View article: Supplementary Figure S4 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S4 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S4: Further characterization of CD8-mIL2 activity in mouse tumor models.
View article: Supplementary Table S2 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Table S2 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Table S2, Antibodies used in this study
View article: Supplementary Table S1 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Table S1 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Table S1, Molecules used in this study
View article: Supplementary Table S3 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Table S3 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Table S3, Single-cell RNA sequencing reagents used in this study
View article: Supplementary Figure S8 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S8 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S8: Differential expression by treatment.
View article: Supplementary Figure S7 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S7 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S7: Sub-clustering of naïve-like/recently activated cluster and characterization of clonal expansion and antigen.
View article: Supplementary Table S1 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Table S1 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Table S1, Molecules used in this study
View article: Supplementary Figure S1 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S1 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S1: CD8+ T cells drive anti-tumor activity but NK cells are responsible for toxicity with not-α-IL2 therapy.
View article: Supplementary Figure S8 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S8 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S8: Differential expression by treatment.
View article: Supplementary Figure S10 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S10 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S10: In vitro and in vivo activity of AB248 in cynomolgus monkey.
View article: Supplementary Figure S2 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S2 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S2: In vitro culture of human CD8+ T cells, evaluation of CD8α and CD8β expression, and cytokine release assessment.
View article: Supplementary Figure S10 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S10 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S10: In vitro and in vivo activity of AB248 in cynomolgus monkey.
View article: Supplementary Figure S9 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S9 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S9: scRNAseq analysis of MC38 tumors.
View article: Supplementary Figure S7 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S7 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S7: Sub-clustering of naïve-like/recently activated cluster and characterization of clonal expansion and antigen.
View article: Supplementary Table S3 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Table S3 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Table S3, Single-cell RNA sequencing reagents used in this study
View article: Supplementary Figure S8 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S8 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S8: Differential expression by treatment.
View article: Supplementary Table S2 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Table S2 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Table S2, Antibodies used in this study
View article: Supplementary Figure S7 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S7 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S7: Sub-clustering of naïve-like/recently activated cluster and characterization of clonal expansion and antigen.
View article: Supplementary Figure S6 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S6 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S6: Characterization of antigen-specific CD8+ T cells in MC38 tumors.
View article: Supplementary Figure S3 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S3 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S3: Biodistribution of cytokine fusion molecules in tumor-bearing mice.
View article: Supplementary Figure S5 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S5 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S5: Anti-tumor activity of CD8-mIL2 in combination with anti-PD-1 in B16F10, 1956, MCA-205, and KP.mLama4 tumor models.
View article: Supplementary Table S1 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Table S1 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Table S1, Molecules used in this study
View article: Supplementary Figure S4 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S4 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S4: Further characterization of CD8-mIL2 activity in mouse tumor models.